MetaVia (MTVA) Competitors $0.78 +0.02 (+2.22%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock MTVA vs. GDTC, BCAB, CLNN, CGTX, DARE, EGRX, TPST, GRCE, CASI, and CARAShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include CytoMed Therapeutics (GDTC), BioAtla (BCAB), Clene (CLNN), Cognition Therapeutics (CGTX), Daré Bioscience (DARE), Eagle Pharmaceuticals (EGRX), Tempest Therapeutics (TPST), Grace Therapeutics (GRCE), CASI Pharmaceuticals (CASI), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. CytoMed Therapeutics BioAtla Clene Cognition Therapeutics Daré Bioscience Eagle Pharmaceuticals Tempest Therapeutics Grace Therapeutics CASI Pharmaceuticals Cara Therapeutics CytoMed Therapeutics (NASDAQ:GDTC) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends. Do institutionals & insiders have more ownership in GDTC or MTVA? 0.0% of CytoMed Therapeutics shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 1.1% of MetaVia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer GDTC or MTVA? CytoMed Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 106.61%. MetaVia has a consensus price target of $12.00, suggesting a potential upside of 1,488.35%. Given MetaVia's higher probable upside, analysts plainly believe MetaVia is more favorable than CytoMed Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00MetaVia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in GDTC or MTVA? CytoMed Therapeutics received 1 more outperform votes than MetaVia when rated by MarketBeat users. CompanyUnderperformOutperformCytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo VotesMetaViaOutperform Votes3100.00% Underperform VotesNo Votes Which has more risk and volatility, GDTC or MTVA? CytoMed Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Comparatively, MetaVia has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Is GDTC or MTVA more profitable? CytoMed Therapeutics' return on equity of 0.00% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets CytoMed TherapeuticsN/A N/A N/A MetaVia N/A -189.12%-122.31% Does the media favor GDTC or MTVA? In the previous week, CytoMed Therapeutics and CytoMed Therapeutics both had 2 articles in the media. CytoMed Therapeutics' average media sentiment score of 1.37 beat MetaVia's score of 0.94 indicating that CytoMed Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MetaVia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, GDTC or MTVA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytoMed TherapeuticsN/AN/A-$3.13MN/AN/AMetaViaN/AN/A-$12.47MN/AN/A SummaryCytoMed Therapeutics beats MetaVia on 5 of the 9 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.54M$6.82B$5.53B$8.03BDividend YieldN/A2.95%5.09%4.22%P/E RatioN/A7.4622.7118.75Price / SalesN/A261.37408.99107.87Price / CashN/A65.8538.1834.62Price / Book0.226.656.844.34Net Income-$12.47M$143.64M$3.22B$248.10M7 Day Performance-8.16%3.55%2.11%2.49%1 Month Performance-50.94%5.90%3.51%4.08%1 Year PerformanceN/A-2.39%16.31%5.67% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia2.1726 of 5 stars$0.78+2.2%$12.00+1,440.6%N/A$6.74MN/A0.008Upcoming EarningsGDTCCytoMed Therapeutics2.1706 of 5 stars$2.40-0.4%$5.00+108.2%+10.0%$26.68MN/A0.00N/APositive NewsBCABBioAtla2.9196 of 5 stars$0.45-8.8%$6.00+1,227.4%-85.2%$26.57M$11M-0.2760Upcoming EarningsNews CoverageCLNNClene3.0637 of 5 stars$2.94-3.1%$50.20+1,610.4%-65.7%$25.93M$342,000.00-0.57100Upcoming EarningsCGTXCognition Therapeutics3.6662 of 5 stars$0.41-1.5%$7.13+1,633.6%-77.1%$25.84MN/A-0.4320Upcoming EarningsShort Interest ↓News CoveragePositive NewsDAREDaré Bioscience2.1573 of 5 stars$2.91+0.7%$24.00+724.7%-26.0%$25.75M$9,784.00-4.9330Short Interest ↓Positive NewsEGRXEagle PharmaceuticalsN/A$1.96+2.1%N/A-53.2%$25.46M$257.55M0.00100Analyst ForecastGap DownTPSTTempest Therapeutics2.0279 of 5 stars$7.19-2.0%$30.00+317.2%-85.4%$25.21MN/A-4.6820Upcoming EarningsGRCEGrace Therapeutics2.7847 of 5 stars$2.44-4.7%$12.00+391.8%N/A$24.74MN/A-2.10N/AAnalyst ForecastNews CoveragePositive NewsGap DownCASICASI Pharmaceuticals3.9537 of 5 stars$1.99-4.3%$4.00+101.0%-14.9%$24.48M$28.54M-0.89180CARACara Therapeutics3.888 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Analyst ForecastPositive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies GDTC Alternatives BCAB Alternatives CLNN Alternatives CGTX Alternatives DARE Alternatives EGRX Alternatives TPST Alternatives GRCE Alternatives CASI Alternatives CARA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTVA Stock Free MTVA Stock Alerts